BioNTech and InstaDeep will host AI Day on October 1, 2025, showcasing AI strategies and applications in healthcare.
Quiver AI Summary
BioNTech SE, in collaboration with InstaDeep Ltd., will host its second AI Day on October 1, 2025, at 9:00 a.m. EDT in London, as part of BioNTech’s “Innovation Series.” The event will showcase BioNTech's AI strategy and its applications within the company's pipeline and processes. A live webcast will be available, with recordings and slides to be accessible later on BioNTech's website. BioNTech is a leader in immunotherapy, focusing on developing innovative cancer treatments and vaccines for infectious diseases, utilizing advanced computational methods and strong collaborations with various pharmaceutical partners. For more details, interested parties can visit BioNTech's website.
Potential Positives
- BioNTech is hosting its second AI Day, highlighting its commitment to integrating artificial intelligence into its pipeline and internal processes, which may enhance innovation and efficiency.
- The event will provide a platform for BioNTech to present its AI strategy, potentially attracting investor interest and demonstrating its forward-thinking approach in biopharmaceuticals.
- BioNTech's collaboration with InstaDeep underscores the company's investment in advanced technologies, positioning it as a leader in the adoption of AI within the biopharmaceutical industry.
- The availability of a live webcast and recordings of the event enhances transparency and allows broader access to stakeholders, reinforcing BioNTech's commitment to investor relations.
Potential Negatives
- The press release does not provide specific details regarding the outcomes or advancements of BioNTech's AI strategy and capabilities, which may lead to skepticism about the effectiveness and transparency of their AI initiatives.
- There is a lack of focus on the company's recent financial performance or strategic challenges, potentially suggesting a disconnect between their innovative presentations and actual business health.
- The upcoming AI Day could be perceived as an attempt to divert attention from potentially pressing issues within the company, such as product development timelines or market competition, without addressing those directly.
FAQ
What is the date and time of BioNTech's second AI Day?
BioNTech's second AI Day is scheduled for October 1, 2025, at 09:00 a.m. EDT (3:00 p.m. CEST).
How can I access the live webcast of the event?
The live webcast of BioNTech's AI Day can be accessed via the link provided in the press release.
Where will the AI Day event take place?
The AI Day will be held in London, United Kingdom.
What information will be presented during AI Day?
The event will cover BioNTech’s AI strategy, capabilities, and the application of AI in its pipeline and processes.
How long will the recording of the event be available online?
The recording will be available shortly after the event and archived on BioNTech’s website for one year.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BNTX Congressional Stock Trading
Members of Congress have traded $BNTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BNTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE VAL T. HOYLE sold up to $15,000 on 08/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$BNTX Hedge Fund Activity
We have seen 112 institutional investors add shares of $BNTX stock to their portfolio, and 182 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. added 3,512,318 shares (+4076.8%) to their portfolio in Q2 2025, for an estimated $373,956,497
- VIKING GLOBAL INVESTORS LP removed 879,972 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $93,690,618
- DODGE & COX added 877,437 shares (+inf%) to their portfolio in Q2 2025, for an estimated $93,420,717
- FMR LLC added 875,600 shares (+12.0%) to their portfolio in Q2 2025, for an estimated $93,225,132
- MILLENNIUM MANAGEMENT LLC removed 544,970 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $58,022,955
- BANK OF NEW YORK MELLON CORP added 410,351 shares (+58.8%) to their portfolio in Q2 2025, for an estimated $43,690,070
- BLACKROCK, INC. removed 351,912 shares (-21.1%) from their portfolio in Q2 2025, for an estimated $37,468,070
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BNTX Analyst Ratings
Wall Street analysts have issued reports on $BNTX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/08/2025
- B of A Securities issued a "Buy" rating on 08/05/2025
- Wells Fargo issued a "Overweight" rating on 08/05/2025
- Truist Securities issued a "Buy" rating on 06/03/2025
- Citigroup issued a "Buy" rating on 05/06/2025
- Morgan Stanley issued a "Overweight" rating on 05/06/2025
To track analyst ratings and price targets for $BNTX, check out Quiver Quantitative's $BNTX forecast page.
$BNTX Price Targets
Multiple analysts have issued price targets for $BNTX recently. We have seen 8 analysts offer price targets for $BNTX in the last 6 months, with a median target of $135.0.
Here are some recent targets:
- Jessica Fye from JP Morgan set a target price of $121.0 on 09/22/2025
- Robert Burns from HC Wainwright & Co. set a target price of $136.0 on 09/08/2025
- Tazeen Ahmad from B of A Securities set a target price of $134.0 on 08/05/2025
- Mohit Bansal from Wells Fargo set a target price of $150.0 on 08/05/2025
- Terence Flynn from Morgan Stanley set a target price of $133.0 on 07/10/2025
- Asthika Goonewardene from Truist Securities set a target price of $155.0 on 06/03/2025
- Asad Haider from Goldman Sachs set a target price of $110.0 on 05/29/2025
Full Release
MAINZ, Germany, September 23, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”), alongside its artificial intelligence (“AI”) company InstaDeep Ltd. (“InstaDeep”), will host its second AI Day, an edition of BioNTech’s “Innovation Series”, at 09:00 a.m. EDT (3:00 p.m. CEST) on Wednesday, October 1, 2025, in London, United Kingdom. The event will provide an overview of BioNTech’s AI strategy and capabilities, and the application of AI in BioNTech’s pipeline and internal processes.
The live webcast of the event will be available via this link .
Participants may also access the slides and a recording of the event via the “Events & Presentations” page in the Investor Relations section of BioNTech’s website at www.BioNTech.com . The recording will be available shortly after the event’s conclusion and archived on BioNTech’s website for one year thereafter.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its diversified portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Bristol Myers Squibb, Duality Biologics, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com .
CONTACTS
Investor Relations
Douglas Maffei, PhD
[email protected]
Media Relations
Jasmina Alatovic
[email protected]
